# US 9,433,659 B2 · Enhanced glycemic control using Ad36E4orf1 and AKT1 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,659 B2
- Document ID: US9433659B2
- Status: Granted
- Kind: B2
- Application number: 14/370,317
- Filed: 2013-01-18
- Published: 2015-02-05
- Granted: 2016-09-06
- Earliest claimed: 2012-01-20
- Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Applicants: Board of Supervisors of Louisiana St. Univ. & Agricultural & Mechanical College
- Inventors: Nikhil Dhurandhar; Rashmi Krishnapuram
- Web page: https://patentgrep.com/patent/US9433659B2

## CPC

- A61K 38/162: {from virus}
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/433: Thidiazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/005: from viruses
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10333: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention generally relates to methods for improving glycemic control by administering an Ad36 composition and an AKT1 inhibitor.

## Claims

### Claim 1

A method of improving glycemic control in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor, wherein glycemic control is improved without substantial increase in adipogenesis.

### Claim 2

A method of increasing insulin sensitivity in an individual, comprising administering to the individual in need thereof a therapeutically effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor, wherein insulin sensitivity is increased without substantial increase in adipogenesis.

### Claim 3

A method of treating hyperglycemia or insulin resistance in the individual, comprising administering to an individual in need thereof a therapeutically effective amount of an Adenovirus-36 (Ad36) E4orf1 protein or a functional variant thereof and a selective AKT1 inhibitor, wherein the individual's symptoms improve without substantial increase in adipogenesis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amino acid sequence of the Adenovirus-36 E4orf1 protein is SEQ ID NO:2 or a functional variant thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said individual is a human.

### Claim 6 (depends on 1)

The method of claim 1, wherein said AKT1 inhibitor is 2-Aminothiadiazole (2-ATD).